Subscribe

Subscribe to our Newsletter and get informed about new publication regulary and special discounts for subscribers!

IJPPE > Volume 4 > The Possible Chemosensitizing Effect of Different...
< Back to Volume

The Possible Chemosensitizing Effect of Different Doses of Indol-3-Carbinol on Transplantable Tumor Model Treated with Doxorubicin

Full Text PDF

Abstract:

Background: Ehrlich carcinoma is a transplantable tumor model used frequently in cancer studies. Doxorubicin (DOX) is one of the anthracyclines that is frequently used in treatment of various types of malignancies including breast, prostate and lung cancer. Indole-3-carbinol (I3C) is a phytochemical that was suggested to have potent anti-tumor and chemosensitizing effects. Objective: To detect the possible chemosensitizing effects of different doses of I3C on solid Ehrlich carcinoma (SEC) treated with DOX in mice. Materials and methods: One hundred and forty mice were divided into seven equal groups as follows: Control untreated group, solid Ehrlich carcinoma (SEC), SEC + DOX, SEC + I3C 1000 ppm, SEC + I3C 2000 ppm, SEC + DOX + I3C 1000 ppm and SEC + DOX + I3C 2000 ppm. Tumor volume, survival rate, tissue glutathione reductase (GR), tissue glutathione peroxidase (GPx), tissue tumor necrosis factor alpha (TNF-α) and tissue interleukin-6 (IL-6) were determined. Parts of the tumor were subjected to histopathological and immunohistochemical examination. Results: DOX and/or I3C produced significant increase in the survival rate, tissue GPx and tissue GR with significant decrease in tumor volume, tissue TNF-α and tissue IL-6 compared to SEC group. Moreover, they improved the histopathological changes with significant increase in tissue caspase-3 activity and p53 compared to SEC group. These effects were significant in DOX/I3C combination groups compared to the use of each of these drugs alone. Conclusion: I3C-in a dose dependent manner - had a chemosensitizing effect against transplantable tumor model treated with DOX in mice and this might represent an adjuvant to the traditional drugs used in cancer chemotherapy.

Info:

Periodical:
International Journal of Pharmacology, Phytochemistry and Ethnomedicine (Volume 4)
Pages:
61-72
Citation:
A. A. Adwas et al., "The Possible Chemosensitizing Effect of Different Doses of Indol-3-Carbinol on Transplantable Tumor Model Treated with Doxorubicin", International Journal of Pharmacology, Phytochemistry and Ethnomedicine, Vol. 4, pp. 61-72, 2016
Online since:
August 2016
Export:
Distribution:
References:

[1] H.I. El-Sayyad et al., Histopathological effects of cisplatin, doxorubicin and 5-flurouracil (5-FU) on the liver of male albino rats, Intl. J. Biol. Sci. 5(2009) 466-473.

DOI: https://doi.org/10.7150/ijbs.5.466

[2] S.E. Al-Harthi et al., Amelioration of doxorubicin-induced cardiotoxicity by resveratrol, Mol. Med. Rep. 10 (2014) 1455-1460.

[3] Y. Wu et al., A Novel Mechanism of Indole-3-Carbinol Effects on Breast Carcinogenesis Involves Induction of Cdc25A Degradation, Cancer Prev. Res. 3 (2010) 818.

[4] X. Wang et al., Indole-3-carbinol inhibits tumorigenicity of hepatocellular carcinoma cells via suppression of microRNA-21 and upregulation of phosphatase and tensin homolog, Biochim. Biophys. Acta. 1853 (2015) 244-253.

DOI: https://doi.org/10.1016/j.bbamcr.2014.10.017

[5] F. Fares, The Anti-Carcinogenic Effect of Indole-3-Carbinol and 3, 3'-Diindolylmethane and their Mechanism of Action, Med. Chem. S1 (2014) 002.

DOI: https://doi.org/10.4172/2161-0444.s1-002

[6] J.C. Hsu et al., Indole-3-carbinol inhibition of androgen receptor expression and downregulation of androgen responsiveness in human prostate cancer cells, Carcinogenesis. 26 (2005)1896-(1904).

DOI: https://doi.org/10.1093/carcin/bgi155

[7] L. Chen et al., Indole-3-carbinol (I3C) increases apoptosis, represses growth of cancer cells, and enhances adenovirus-mediated oncolysis, Cancer Biol. Ther. 15 (2014) 1256-1267.

DOI: https://doi.org/10.4161/cbt.29690

[8] C.N. Marconett, A.K. Singhal, S.N. Sundar, G.L. Firestone, Indole-3-carbinol disrupts estrogen receptor-alpha dependent expression of insulin-like growth factor-1 receptor and insulin receptor substrate-1 and proliferation of human breast cancer cells, Mol. Cell. Endocrinol. 363 (2012).

DOI: https://doi.org/10.1016/j.mce.2012.07.008

[9] A.M. Kabel, Effect of Combination between Methotrexate and Histone Deacetylase Inhibitors on Transplantable Tumor Model, Am. J. Med. Studies. 2 (2014) 12-18.

[10] I. Tekedereli et al., Therapeutic Silencing of Bcl-2 by Systemically Administered siRNA Nanotherapeutics Inhibits Tumor Growth by Autophagy and Apoptosis and Enhances the Efficacy of Chemotherapy in Orthotopic Xenograft Models of ER (−) and ER (+) Breast Cancer, Molecular Therapy—Nucleic Acids. 2 (2013).

DOI: https://doi.org/10.1038/mtna.2013.45

[11] L.E. Shorey et al., Differential modulation of dibenzo[def, p]chrysene transplacental carcinogenesis: maternal diets rich in indole-3-carbinol versus sulforaphane, Toxicol. Appl. Pharmacol. 270 (2013) 60–69.

DOI: https://doi.org/10.1016/j.taap.2013.02.016

[12] Z. Yu et al., Indole-3-carbinol in the maternal diet provides chemoprotection for the fetus against transplacental carcinogenesis by the polycyclic aromatic hydrocarbon dibenzo[a, l]pyrene, Carcinogenesis. 27 (2006) 2116–2123.

DOI: https://doi.org/10.1093/carcin/bgl072

[13] S.K. Jaganathan et al., Effect of Honey and Eugenol on Ehrlich Ascites and Solid Carcinoma, J. Biomed. Biotechnol. 2010 (2010) Article ID 989163.

[14] C. Manso, F. Wroblewski, Glutathione reductase activity in blood and body fluids, J. Clin. Invest. 37 (1958) 214–218.

DOI: https://doi.org/10.1172/jci103600

[15] J.T. Rotruck et al., Selenium: biochemical role as a component of glutathione peroxidase, Science. 179 (1973) 588-590.

DOI: https://doi.org/10.1126/science.179.4073.588

[16] U. Manne, H.L. Weiss, R.B. Myers, O.K. Danner, Nuclear accumulation of p.53 in colorectal adenocarcinomas: prognostic importance differs with race and location of tumour, Cancer. 83 (1998) 2456–2467.

DOI: https://doi.org/10.1002/(sici)1097-0142(19981215)83:12<2456::aid-cncr8>3.0.co;2-5

[17] A.M. Fayez et al., Beneficial effects of thymoquinone and omega-3 in intestinal ischemia/R-induced renal dysfunction in rats, BFOP-CU. 52 (2014) 171–177.

[18] A.M. Kabel, M.A. El-Rashidy, M.S. Omar, Ameliorative Potential of Tamoxifen/Thymoquinone Combination in Patients with Breast Cancer: A Biochemical and Immunohistochemical Study, Cancer Med. Anticancer Drug. 1 (2016) 102.

[19] R.S. Kumar et al., Antitumor Activity of Prosopis glandulosa Torr. on Ehrlich Ascites Carcinoma (EAC) Tumor Bearing Mice, Iran. J. Pharm. Res. 10 (2011) 505-510.

[20] A.M. Kabel et al., Effect of atorvastatin and methotrexate on solid Ehrlich tumor, Eur. J. Pharmacol. 713 (2013) 47-53.

[21] F.M. Metwally, H.A. El-Mezayen, A.E. Abdel Moneim, N.E. Sharaf, Anti-Tumor Effect of Azadirachta indica (Neem) on Murine Solid Ehrlich Carcinoma, Acad. J. Cancer Res. 7 (2014) 38-45.

[22] B. Xiu et al., IL-10 induces the development of immunosuppressive CD14+HLA-DRlow/− monocytes in B-cell non-Hodgkin lymphoma, Blood Cancer J. 5 (2015) e328.

DOI: https://doi.org/10.1038/bcj.2015.56

[23] Z. Culig, Cytokine disbalance in common human cancers, Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1813(2) (2011) 308–314.

DOI: https://doi.org/10.1016/j.bbamcr.2010.12.010

[24] H.A. Smith, Y. Kang, The Metastasis-Promoting Roles of Tumor-Associated Immune Cells, Journal of molecular medicine (Berlin, Germany). 91 (2013) 411-429.

[25] S. Saraswati, S.S. Agrawal, A.A. Alhaider, Ursolic acid inhibits tumor angiogenesis and induces apoptosis through mitochondrial-dependent pathway in Ehrlich ascites carcinoma tumor, Chem. Biol. Interact. 206 (2013) 153-165.

DOI: https://doi.org/10.1016/j.cbi.2013.09.004

[26] A.M. Kabel, Tumor protein p.53: Novel aspects of an old tumor marker, JCRT. 3 (2015) 25-27.

[27] S.M. El-Dayem, F.M. Fouda, E.H. Ali, B.A. Motelp, The antitumor effects of tetrodotoxin and/or doxorubicin on Ehrlich ascites carcinoma-bearing female mice, Toxicol. Ind. Health. 29 (2013) 404-417.

DOI: https://doi.org/10.1177/0748233711434955

[28] A.M. Osman et al., Chemosensetizing and cardioprotective effects of resveratrol in doxorubicin-treated animals, Cancer Cell International. 13 (2013) 52.

DOI: https://doi.org/10.1186/1475-2867-13-52

[29] A. Das et al., Sildenafil increases chemotherapeutic efficacy of doxorubicin in prostate cancer and ameliorates cardiac dysfunction, Proceedings of the National Academy of Sciences of the United States of America. 107 (2010) 18202-18207.

DOI: https://doi.org/10.1073/pnas.1006965107

[30] S. Wang et al., Evodiamine Synergizes with Doxorubicin in the Treatment of Chemoresistant Human Breast Cancer without Inhibiting P-Glycoprotein, PLoS ONE. 9 (2014) e97512.

DOI: https://doi.org/10.1371/journal.pone.0097512

[31] T. Takahashi, Studies on molecular mechanism of toxicity of anticancer drugs, Yakugaku Zasshi. 131 (2011) 355-358.

DOI: https://doi.org/10.1248/yakushi.131.355

[32] F. Yang, S.S. Teves, C.J. Kemp, S. Henikoff, Doxorubicin, DNA torsion, and chromatin dynamics, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 1845 (2014) 84–89.

DOI: https://doi.org/10.1016/j.bbcan.2013.12.002

[33] A. Arora, K. Seth, N. Kalra, Y. Shukla, Modulation of P-glycoprotein-mediated multidrug resistance in K562 leukemic cells by indole-3-carbinol, Toxicol. Appl. Pharmacol. 202 (2005) 237-243.

DOI: https://doi.org/10.1016/j.taap.2004.06.017

[34] C.G. Mao et al., Indole-3-carbinol inhibits nasopharyngeal carcinoma cell growth in vivo and in vitro through inhibition of the PI3K/Akt pathway, Exp. Ther. Med. 8 (2014) 207-212.

DOI: https://doi.org/10.3892/etm.2014.1696

[35] A. Acharya, I. Das, S. Singh, T. Saha, Chemopreventive properties of indole-3-carbinol, diindolylmethane and other constituents of cardamom against carcinogenesis, Recent Pat. Food Nutr. Agric. 2 (2010) 166-177.

DOI: https://doi.org/10.2174/2212798411002020166

[36] M. De Santi, L. Galluzzi, A. Duranti, M. Magnani, G. Brandi, The Indole-3-carbinol cyclic tetrameric derivative CTet synergizes with cisplatin and doxorubicin in triple-negative breast cancer cell lines, Anticancer Res. 33 (2013) 1867-1872.

DOI: https://doi.org/10.1186/bcr2855
Show More Hide
Cited By:
This article has no citations.